Mizuho states that Merck has better diversified its revenue,...

Mizuho states that Merck has better diversified its revenue, lessening dependency on KEYTRUDA. Other candidates across multiple therapeutic areas may also contribute, relieving revenue pressure from KEYTRUDA's potential patent expiry and pricing pressures.